Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry

Brioli A, Lomaia E, Fabisch C, Sacha T, Klamova H, Morozova E, Golos A, Ernst P, Olsson-Stromberg U, Zackova D, Nicolini FE, Bao H, Castagnetti F, Patkowska E, Mayer J, Hirschbühl K, Podgornik H, Paczkowska E, Parry A, Ernst T, Voskanyan A, Szczepanek E, Saussele S, Franke GN, Kiani A, Faber E, Krause S, Casado LF, Lewandowski K, Eder M, Anhut P, Gil J, Südhoff T, Hebart H, Heibl S, Pfirrmann M, Hochhaus A, Lauseker M (2024)


Publication Type: Journal article

Publication year: 2024

Journal

DOI: 10.1038/s41375-024-02204-y

Abstract

Blast phase (BP) of chronic myeloid leukemia (CML) still represents an unmet clinical need with a dismal prognosis. Due to the rarity of the condition and the heterogeneity of the biology and clinical presentation, prospective trials and concise treatment recommendations are lacking. Here we present the analysis of the European LeukemiaNet Blast Phase Registry, an international collection of the clinical presentation, treatment and outcome of blast phases which had been diagnosed in CML patients after 2015. Data reveal the expected heterogeneity of the entity, lacking a clear treatment standard. Outcomes remain dismal, with a median overall survival of 23.8 months (median follow up 27.8 months). Allogeneic stem cell transplantation (alloSCT) increases the rate of deep molecular responses. De novo BP and BP evolving from a previous CML do show slightly different features, suggesting a different biology between the two entities. Data show that outside clinical trials and in a real-world setting treatment of blast phase is individualized according to disease- and patient-related characteristics, with the aim of blast clearance prior to allogeneic stem cell transplantation. AlloSCT should be offered to all patients eligible for this procedure.

Authors with CRIS profile

Involved external institutions

Institute of Hematology after Prof. R.H. Yeolyan / ՊՐՈՖԵՍՈՐ Ռ.Հ. ՅՈԼՅԱՆԻ ԱՆՎԱՆ ԱՐՅՈՒՆԱԲԱՆԱԿԱՆ ԿԵՆՏՐՈՆ AM Armenia (AM) Jagiellonian University Medical College PL Poland (PL) Universitätsklinikum Mannheim DE Germany (DE) Universität Leipzig DE Germany (DE) First Pavlov State Medical University of St. Petersburg RU Russian Federation (RU) Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im. Ks. B. Markiewicza PL Poland (PL) Instytut Centrum Zdrowia Matki Polki w Łodzi (ICZMP) / Polish Mother’s Memorial Hospital Research Institute PL Poland (PL) Klinikum Passau DE Germany (DE) Universitätsklinikum Jena DE Germany (DE) Stauferklinikum Schwäbisch Gmünd DE Germany (DE) Universitätsmedizin Greifswald / Universitätsklinikum Greifswald DE Germany (DE) University Hospital Olomouc / Fakultní Nemocnice Olomouc CZ Czech Republic (CZ) University Hospital of Toledo / Hospital Universitario de Toledo ES Spain (ES) Poznan University of Medical Sciences / Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu PL Poland (PL) Medizinische Hochschule Hannover (MHH) / Hannover Medical School DE Germany (DE) Onkologische Schwerpunktpraxis Bielefeld DE Germany (DE) Federal Almazov Medical Research Centre RU Russian Federation (RU) Uppsala University Hospital / Akademiska sjukhuset SE Sweden (SE) Klinikum Wels-Grieskirchen AT Austria (AT) University Hospital Brno CZ Czech Republic (CZ) Ludwig-Maximilians-Universität (LMU) DE Germany (DE) Centre Léon-Bérard (UNICANCER) FR France (FR) Ospedaliero Universitaria di Bologna Policlinico S.Orsola-Malpighi IT Italy (IT) Institute of Hematology and Blood Transfusion / Instytut Hematologii i Transfuzjologi (IHiT) PL Poland (PL) Universität Augsburg DE Germany (DE) Ljubljana University Medical Centre (Ljubljana UMC) / Univerzitetni klinični center Ljubljana SI Slovenia (SI) Pomeranian Medical University / Pomorski Uniwersytet Medyczny w Szczecinie (PMU) PL Poland (PL) Centre Hospitalier Annecy Genevois FR France (FR)

How to cite

APA:

Brioli, A., Lomaia, E., Fabisch, C., Sacha, T., Klamova, H., Morozova, E.,... Lauseker, M. (2024). Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry. Leukemia. https://doi.org/10.1038/s41375-024-02204-y

MLA:

Brioli, Annamaria, et al. "Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry." Leukemia (2024).

BibTeX: Download